Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma

Up to 40% of patients with advanced Hodgkin lymphoma (HL) become refractory or relapsed after current standard chemotherapy, among which primary refractory HL confers a particularly poor outcome. With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hung-Bo, Yeh, Shyh-An, Chen, Huei-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808109/
https://www.ncbi.nlm.nih.gov/pubmed/24198983
http://dx.doi.org/10.1155/2013/351292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808109/
https://www.ncbi.nlm.nih.gov/pubmed/24198983
http://dx.doi.org/10.1155/2013/351292

Ejemplares similares